Quest acquires Enterix for $43m:
This article was originally published in Clinica
Quest Diagnostics has completed the acquisition of Enterix, the provider of its colorectal cancer screening product, the InSure Fecal Immunochemical Test. It paid $43m in cash to acquire the privately-held company, which has operations in Sydney, Australia, and Falmouth, Maine. Quest has sold InSure FIT exclusively in the US since May 2003.